The Overdose Toolkit We Built Doesn't Cover the Drugs Now Filling the Gap

Every reversal drug on a first responder’s belt, every fentanyl test strip handed out at a syringe exchange, every buprenorphine prescription filled at a clinic — the entire toolkit built over the last decade to stop overdose deaths was built for one drug class: opioids. That bet paid off. The newest CDC data brief shows the overdose death rate fell 26.2 percent from 2023 to 2024, the steepest drop on record, with deaths involving fentanyl and other synthetic opioids down 35.6 percent in a single year.

But look at what’s underneath that headline number. A peer-reviewed analysis published in August found that overdose deaths involving stimulants — methamphetamine, cocaine — with no opioid present kept climbing through 2024: cocaine deaths without opioids up 1.7 percent, methamphetamine deaths without opioids up 2.4 percent, even as the national curve bent sharply down.

We spent ten years building an overdose response for one drug, and the crisis is quietly leaving that lane.

To be precise about what the data does and doesn’t show: nationally, opioids are still involved in far more overdose deaths than stimulants alone — CDC’s own count puts opioid-involved deaths at 44,564 of an estimated 69,973 total in 2025, both categories falling. Stimulants haven’t “overtaken” opioids as the nation’s biggest killer; that claim overstates it. What’s real is narrower, and in its way worse: the one slice of the overdose map still growing is built almost entirely from drugs the fentanyl-focused toolkit doesn’t touch. The growth is sharpest regionally — meth deaths without opioids present rose 26.7 percent in a single year in the Northeast; in Spokane County, Washington, a University of Washington researcher told the local paper meth deaths have grown roughly six times faster than opioid deaths there over two decades. That’s regional, not a national reversal — but it’s the line still climbing while the opioid line falls.

Here’s the plain-language version of why that split matters. “Polysubstance” just means using more than one drug at a time, and for years, most stimulant deaths were also opioid deaths — someone using meth or cocaine that was secretly cut with fentanyl, dying of an opioid overdose that happened to involve a stimulant too. Naloxone reverses that death, because an opioid is what’s stopping the person’s breathing. But a death from stimulants alone — a heart that gives out, a stroke, a body that overheats — isn’t an opioid problem, and naloxone does nothing for it. There is no FDA-approved medication that reliably treats stimulant use disorder the way buprenorphine and methadone treat opioid addiction, and no equivalent of naloxone exists for a pure stimulant overdose at all.

If you use meth or cocaine right now, and someone near you goes down from it and it isn’t fentanyl, there is no shot to give them. That gap isn’t hypothetical — it’s the exact reason “stimulant use disorder” is starting to worry the people who run treatment programs. Dr. Dheeraj Raina, managing medical director at Carelon Behavioral Health, put the imbalance bluntly: the field keeps reaching for medication as the answer, he said, even though contingency management — a behavioral incentive program, not a pill — is “the most effective, proven intervention for stimulant use disorder,” and it remains chronically underfunded next to the infrastructure opioids got.

CDC just opened a new public Overdose Prevention Data Channel timed to International Overdose Awareness Day, built to track exactly this kind of divergence in near-real time. The dashboard is the easy part. The hard part is that we spent a decade making one shape of overdose survivable, and people who use stimulants are still waiting on their version of the shot.

CDC just opened a new public Overdose Prevention Data Channel timed to International Overdose Awareness Day, built to track exactly this kind of divergence in near-real time.